Mountain Valley MD Holdings Inc. (MVMD) announced it is commencing husbandry animal trials with a third-party preclinical contract research organization (CRO) to validate the superiority of the Company's injectable solubilized Ivermectin technology, IvectosolTM 1%, versus current commercially available forms to treat a broad category of animal parasites. MVMD's Ivectosol 1% will be tested in swine and poultry by way of advanced intra- muscular needleless injection to prove superior pharmacokinetics in terms of CMAX (peak serum concentration that a drug achieves) and AUC (area under the curve) with targeted drug withdrawal times within 10 days of administration. Additionally, the study is anticipated to demonstrate superior ease of administration with elimination of typically heavy restraint requirements, elimination of injection pain for the animal, while dramatically reducing the risk of potentially fatal clostridial infection common with traditional injection site penetration from large gauge needles. The Company's Ivectosol 1% solution uses no harmful organic solvents and is the viscosity of water, which enables novel needleless injector applications. The Company believes the use of needle-free injection systems with a solubilized Ivermectin will deliver significant benefits to livestock and poultry producers, including increased efficacy and elimination of needles that transfer disease and risk of breaking into food supply, improved administration simplicity with reduced labour and safer handling protocols, minimized tissue damage that traditionally negatively impacts yields, and precision dosing that helps to eliminate human error. Proceeding with the animal trial is part of the Company's plan to pursue the broad husbandry and companion animal markets with its IvectosolTM 1% technology, focused immediately on cattle, swine and poultry industries with a combined annual consumption market size of more than 67 billion animals. MVMD plans to evolve its testing after the current trials are completed to demonstrate the efficacy of its proprietary IvectosolTM 1% solution in protecting fowl against Avian influenza viruses such as H5N8 and H5N1, opening the door for broad flock protection against these rapidly spreading viruses. The Company's previously completed pre-clinical trial work with a third-party Contract Research Organization tested the solubilized Ivermectin via both an intramuscular injection and applied to rapid dissolve oral format with the Company's patented QuicksomeTM desiccated liposome technology compared to existing oral and subcutaneous injection solutions. The results demonstrated that the Company's patented QuicksolTM solubilized Ivermectin offered superior pharmacokinetic performance across every single measure conducted, with no adverse side effects using up to 1/8 less of the Ivermectin drug ­ a critical component that enables applications to use less of the Ivermectin drug while driving faster viral clearance. As previously communicated, MVMD's solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity.